- Research article
- Open Access
- Open Peer Review
PTPRC(CD45) is not associated with multiple sclerosis in a large cohort of German patients
© Miterski et al; licensee BioMed Central Ltd. 2002
- Received: 7 February 2002
- Accepted: 16 May 2002
- Published: 16 May 2002
Since contradictory results have been reported, we reanalysed the 77C→G transition in exon 4 of the protein-tyrosine phosphatase receptor-type C (PTPRC also known as CD45) in a large cohort of German MS patients and controls. Different isoforms of the protein are expressed, depending on alternative splicing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC) (CD45RO, exons 4–6 spliced out). The 77C→G transition does not change the amino acid sequence, but it is probably part of a motif necessary for splicing leading to the isoform CD45RA. The expression of CD45RA is increased in 77C/G heterozygous individuals. The aim of the study was to clarify the importance of the PTPRC 77C→G transition in our German cohort of MS patients.
PCR products of exon 4 were digested using endonuclease MspI. The resulting restriction fragments of the wildtype C allele are 198 and 62 bp in length. In the G allele an additional restriction site is present yielding fragments of 114 and 84 bp.
The G allele was identified in 10 of the 347 controls (1.4%) and in 7 of 454 MS patients (0.8%; Table 1). No homozygous individuals were found either in the control or in the patient group. Genetic association between the PTPRC 77C→G transition and MS susceptibility was excluded in the MS cohort. In addition, subgrouping patients according to differences in the clinical course of MS or according to HLA-DRB1*15 status did not yield significant differences.
The 77C→G transition in exon 4 of the PTPRC gene may contribute to MS susceptibility only in very few families, if at all, but it is not relevant for the majority of MS cases, including virtually all German patients.
- Multiple Sclerosis
- Multiple Sclerosis Patient
- Expand Disability Status Scale
- Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
Allele frequency of the 77C→G transition in PTPRC. Homozygosity was not observed.
C allele (%)
G allele (%)
Controls (N = 347)
MS patients (N = 454)
RRMS (N = 219)
SPMS (N = 92)
PPMS (N = 70)
HLA-DRB1 * 15 MS patients (N = 161)
Peripheral blood samples from more than 400 healthy blood donors were obtained with their informed consent, and provided by the department of transplantation and immunology of the University Hospital Eppendorf (Hamburg, Germany). The mean age of the healthy donors was 39.3 ± 11.47 years. The male/female ratio was 1.4 ± 0.5. More than 800 unrelated MS patients attending the Department of Neurology, University clinics of Bochum and Göttingen (Germany) participated in this study. The male/female ratio was 1.7 ± 0.47, the mean age at MS onset was 29.9 ± 9.63 years. 55.3% of all clinically diagnosed MS patients exhibited a relapsing/remitting course of MS (RRMS), 25.8% developed secondary progressive MS (SPMS) and 18.9% were characterized by primary progressive MS (PPMS). The mean EDSS (expanded disability status scale) of all MS patients was 4.2 ± 2.31, of PPMS 5.8 ± 1.91 and of RRMS+SPMS 3.9 ± 2.25 .
The rare G allele was present in 10 of the 347 controls (1.4%) and in 7 of 454 MS patients (0.8%; Table 1). There were no homozygous individuals either in the control or patient groups. Genetic association between the PTPRC 77C→G transition and MS susceptibility was excluded in the MS cohort. In addition, subgrouping patients according to differences in the clinical course of MS (RRMS, SPMS, PPMS) or according to HLA-DRB1*15 status did not yield significant differences.
This result contradicts the findings of Jacobsen et al. who demonstrated an association of the mutation with MS in 3 families. Barcellos et al. and Vorechovsky et al.  excluded MS association as well. However, as yet unknown polymorphisms in the PTPRC gene may contribute to MS susceptibility.
In conclusion, the PTPRC exon 4 77C→G transition seems to contribute to MS susceptibility only in a few families, if at all, but it is not relevant for the majority of MS cases, also not in virtually all German patients.
We would like to thank the MS patients for participating in this study, Susann Schiwy, Gudrun Rodepeter and Margret Schumacher for excellent technical assistance and Professor David Ballantyne for his expert corrections of the scientific English. This work was supported by BMBF (01GG9841).
- Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R, Wonigeit K, Lindert R-B, Kantarci O, Schaefer-Klein J, Schipper HI, Oertel WH, Heidenreich F, Weinshenker BG, Sommer N, Hemmer B: A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet. 2000, 26: 495-499. 10.1038/82659.View ArticlePubMedGoogle Scholar
- Barcellos LF, Caillier S, Dragone L, Elder M, Vittinghoff E, Bucher P, Lincoln RR, Pericak-Vance M, Haines JL, Weiss A, Hauser SL, Oksenberg JR: PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients. Nat Genet. 2001, 29: 2323-24. 10.1038/ng722.View ArticleGoogle Scholar
- Vorechovsky I, Kralovicova J, Tchilian E, Masterman T, Zhang Z, Ferry B, Misbah S, Chapel H, Webster D, Hellgren D, Anvret M, Hillert J, Hammarstrom L, Beverley PC: Does 77C→G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus?. Nat Genet. 2001, 29: 22-23. 10.1038/ng723.View ArticlePubMedGoogle Scholar
- Thude H, Hundrieser J, Wonigeit K, Schwinzer R: A point mutation in the human CD45 gene associated with defective splicing of exon A. Eur J Immunol. 1995, 25: 2101-2106.View ArticlePubMedGoogle Scholar
- Miterski B, Böhringer S, Klein W, Sindern E, Haupts M, Schimrigk S, Epplen JT: Inhibitors in the NFκB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes and Immunity. 2002,Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/3/3/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.